Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Ondine Biomedical, Inc. ( (GB:OBI) ) has issued an announcement.
Ondine Biomedical Inc.’s CEO, Carolyn Cross, alongside her husband, Robert Cross, has increased their stake in the company by purchasing 149,225 common shares. This move comes as the company progresses through a Phase 3 clinical trial for its light-activated antimicrobial treatments. The acquisition of shares reflects the CEO’s confidence in Ondine’s strategic direction and its potential impact on the market, signaling positive implications for stakeholders as the company advances its product development and regulatory approval processes.
More about Ondine Biomedical, Inc.
Ondine Biomedical Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies, known as photodisinfection. The company has a range of investigational products based on its proprietary technology, targeting medical conditions such as chronic sinusitis, ventilator-associated pneumonia, and burns. Its nasal photodisinfection system, Steriwave®, is approved in Canada and several other countries and is currently undergoing clinical trials in the US.
YTD Price Performance: 42.86%
Average Trading Volume: 520,482
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £50.5M
See more data about OBI stock on TipRanks’ Stock Analysis page.
